Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03289832 · ClinicalTrials.gov registry record · NA

Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin

A NA study of Healthy Adults, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT03289832: Completed NA study of Healthy Adults, sponsored by Johns Hopkins University.

NCT03289832 is a NA study of Healthy Adults that has completed, run by Johns Hopkins University. The registered enrollment target is 25 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03289832, a NA study of Healthy Adults, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The objective is to determine, in a small number of participants, the protective effects of UV-induced skin erythema (reddening or "sunburn") following oral administration of sulforaphane, curcumin, or a combination of the two plant (diet)-based supplements. The investigators will be using the over-the-counter nutritional supplements Crucera-SGS and Meriva-SF to deliver the biologically stable sulforaphane precursor and a highly bioavailable formulation of curcumin. Volunteers will be challenged with UV irradiation at 2-times the minimum erythematous dose (M.E.D.) on discrete 2 cm diameter circles on the upper buttocks. Skin redness will be monitored daily using a chromometer. Biomarkers will then be evaluated in blood, urine, and skin biopsies.

Primary Outcome

Brief ultraviolet (UV) exposure on small circular spots on the skin will produce erythema (reddening), to be measured with a chromameter and photographed in the days following UV exposure, both before and after subjects have ingested study supplement (Crucera SGS, Meriva 500-SF, or both), daily, for a week. These measures will be compared to erythema in the skin of the same individuals following UV exposure, but WITHOUT having ingested these supplements.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Crucera-SGS
  • DIETARY_SUPPLEMENT Meriva 500-SF

Study Locations (1)

Maryland

  • Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2017-09-25
Est. Completion 2019-10-23
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT03289832 record still lists

NCT03289832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 2 interventions - of which Crucera-SGS is the first listed.

NCT03289832 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03289832 about?

NCT03289832 is a clinical study titled "Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin". The objective is to determine, in a small number of participants, the protective effects of UV-induced skin erythema (reddening or "sunburn") following oral administration of sulforaphane, curcumin, or a combination of the two plant (diet)-based supplements. The investigators will be using the over-...

What is the current status of trial NCT03289832?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2017-09-25. Estimated completion is 2019-10-23.

What conditions does trial NCT03289832 study?

This clinical trial studies the following conditions: Healthy Adults.

What interventions are being tested in trial NCT03289832?

The interventions under investigation include: Crucera-SGS (DIETARY_SUPPLEMENT), Meriva 500-SF (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03289832?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03289832 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adults

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03289832's enrollment target sits among peer trials

25 26th of 33 higher than 8 of 33 other Healthy Adults trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adults trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03289832, the US trial registry maintained by the National Library of Medicine. NCT03289832 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.